[ Inglês] Multiple Pathways to Target CLL Cells: Combination Therapy Update

Published on

Topics include: Treatments

Clinical research on combination therapies to treat chronic lymphocytic leukemia (CLL) is creating a buzz in the world of cancer care. How does this treatment strategy work? What medicines are being combined? CLL specialist, Dr. Nicole Lamanna from Columbia University Medical Center, gives insight from an expert perspective on the efficacy of the combination therapy approach. Dr. Lamanna also shares what clinical trials are investigating to drive the development of combination therapies. Watch now to hear how today’s researchers are using this treatment method to improve CLL care. 

Provided by CLL Global Research Foundation, which received support from AbbVie Inc., Gilead Sciences, Inc., Pharmacyclics LLC and TG Therapeutics. It is produced by Patient Power in collaboration with The University of Texas MD Anderson Cancer Center.

View more programs featuring and

Produced in association with and

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Jeff Folloder:               

Dr. Lamanna, we’ve talked about some of the tools in the toolbox, but one of the things that I read a lot about online, and I’m sure the audience is really interested in, is this whole idea of combination therapies. Taking bits and pieces of different treatments and combining them. What is going on with combination therapy? 

Dr. Lamanna:              

Yeah, so as you’ve heard, we went from really traditional chemo immunotherapy, and sort of non-specific, right?

So it targeted the leukemia cells but also targeted other immune effector cells, and your good cells, and now we worked from, to MABs, to now pathway inhibitors. So, now, you see that we’re getting more and more targeted, and we’re getting more and more directed at trying to kill the leukemia cells, without hurting your own immune system, and so, in doing so, we’re looking for different ways, can we combine some of these agents together? Can we look at looking at more than one pathway to target, so we can inhibit the CLLs from either growing, or migrating, and impact the cells that sorta support them, in multiple ways? So can we effect the cancer cells, by targeting multiple pathways, that might affect, obviously increase the likelihood of killing these cells?

And so, you’re seeing lots of strategies, that are looking at combining, whether it be a monoclonal antibody, plus one of these new oral agents, whether we can combine more than one of these oral agents, that are targeting the pathways differently, together. 

That’s what a lot of the clinical trials are looking at, how can we better impact the response that folks are—how can we kill more of these leukemia cells, but at the same time, obviously, be conscious of the fact that we don’t wanna effect your immune system or hurt you in the process. So there are lots of different clinical trials, trying to look at these different avenues. Now that we’re getting a lot more focus, we’re understanding the biology about CLL a lot better, you see we’re moving away from this sort of less specific killing of everything, to more targeted therapies. And impacting the leukemia, and hopefully improving the quality of life of our patients, and certainly the survival of our patients has improved. 

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

Combination Therapy: Are Two Drugs More Effective to Combat CLL?

What does the data show on the efficacy of CLL combination therapies? CLL xperts Dr. William Wierda and Dr. Anthony Mato joined us at ASH 2017 to share the latest results from clinical trial research.

Published:

Novel CLL Drugs in Development

What could be coming soon from the CLL treatment pipeline? Watch now to discover the way modern therapies are designed and how they work to target CLL cells.

Published:

Genetic Testing: What Version of CLL Do I Have and How Do I Treat It?

What do doctors look for in genetic tests for CLL patients? How do the results affect the course of treatment? Find out now from CLL expert Dr. Jennifer Brown.

Published:

Advertisement
Junte-se a nossa comunidade Cadastre-se para Eventos Leia nosso último blog
Advertisement

Page last updated on May 8, 2018